ClinicalTrials.gg
Not yet recruitingNCT07943416Updated Nov 17, 2026

AI-Assisted Management of Diabetes and Hypertension in Primary Care

An interventional study of LLM-assisted Clinical Decision Support and Remote Specialist Consultation in Type 2 Diabetes (T2DM) and Hypertension, sponsored by Jiangsu Taizhou People's Hospital. Not yet recruiting. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Jiangsu Taizhou People's Hospital · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9,245
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

Brief Summary:

Many older adults in rural areas suffer from both type 2 diabetes and high blood pressure. Managing these two conditions at the primary care level is often challenging. This study aims to find out if a new "village doctor-led digital management model" can help improve patient health compared to the current standard care.

Who can participate? Adults aged 60 or older who have been diagnosed with both type 2 diabetes and high blood pressure, whose current blood sugar or blood pressure is not well-controlled, and who receive care at local village clinics.

How does the study work?

Village clinics will be randomly assigned to one of two groups:

Usual Care Group: Patients receive standard national primary health services.

Integrated Care Group: In addition to standard care, village doctors will use an Artificial Intelligence (AI) system. This system provides clinical suggestions to the village doctors, helps arrange remote consultations with hospital specialists if needed, and gives patients personalized advice on diet and exercise.

What are we measuring? We will follow participants for up to 3 years. The main goals are to see if the new AI-assisted model improves the control of blood sugar, blood pressure, and cholesterol at 12 months, and whether it reduces the risk of severe cardiovascular events (like heart attacks or strokes) over 36 months.

02

Conditions studied

  • Type 2 Diabetes (T2DM)
  • Hypertension
03

In context

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's planned enrollment of 9,245 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Jiangsu Taizhou People's Hospital is the lead sponsor of 17 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

IInclusion Criteria:

Age ≥ 60 years. Previously diagnosed with both type 2 diabetes mellitus and hypertension. Inadequate glycemic control ( ≥ 7.5%; or HbA1c ≥ 8.0% if accompanied by clinical cardiovascular disease) OR inadequate blood pressure control (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg).

Signed a family doctor service agreement with the local village doctor. Agree to participate in the study and provide written .

Exclusion Criteria:

Severe physical or psychological problems. Unable to attend on-site visits. Unable to answer questions independently. Unable to reside in the participating community for more than 1 year. less than 3 years. Participated in any other clinical trial within the past 6 months.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
9,245 participants (estimated)

Study arms

  • Experimental
    Integrated Care Group

    Village doctor-led integrated digital management, including LLM-assisted decision support, remote specialist collaboration, and individualized lifestyle intervention.

    Other: LLM-assisted Clinical Decision Support · Other: Remote Specialist Consultation · Other: Usual care according to the National Basic Public Health Service requirements.

  • Other
    Usual Care Group

    Usual care according to the National Basic Public Health Service requirements.

    Other: Usual care according to the National Basic Public Health Service requirements.

Interventions

  • OtherLLM-assisted Clinical Decision Support

    A digital platform that integrates patient data and uses a large language model to provide risk alerts and management suggestions to village doctors for review.

  • OtherRemote Specialist Consultation

    Village doctors can initiate remote consultations with specialists (e.g., endocrinology, cardiology) through the platform for complex or poorly controlled cases.

  • OtherUsual care according to the National Basic Public Health Service requirements.

    Usual care according to the National Basic Public Health Service requirements.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving at least 2 of 3 ABC goals at 12 months

    The proportion of participants achieving at least two of the following three predefined goals at 12 months post-randomization: A (HbA1c control), B (Blood pressure control), and C (LDL-C control).

    Time frame: 12 months post-randomization

  2. Time to first Major Adverse Cardiovascular Event (MACE) within 36 months

    The time from randomization to the first occurrence of a Major Adverse Cardiovascular Event (MACE) within 36 months.

    Time frame: Up to 36 months post-randomization

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.

Of 2,068 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 36 months is above that.

Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 17, 2026
StartEst.
Nov 14, 2026
Primary completionEst.
Nov 14, 2029
CompletionEst.
Nov 14, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943416
Lead sponsor
Jiangsu Taizhou People's Hospital
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 14, 2026 (estimated)
Primary completion
Nov 14, 2029 (estimated)
Completion
Nov 14, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Ming Chu
Contact
18061986120@189.cn
18061986120

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion